%0 Journal Article
%T Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
%A Dmitry Alekseevich Sychev
%A Dmitry Dmitrievich Markov
%A Elena Anatolievna Grishina
%A Evgeny Alekseevich Bryun
%A Ludmila Mikhailovna Savchenko
%A Mikhail Sergeevich Zastrozhin
%A Nataliya Petrovna Denisenko
%A Valentin Yurievich Skryabin
%J Archive of "Pharmacogenomics and Personalized Medicine".
%D 2018
%R 10.2147/PGPM.S160763
%X Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotransformation of fluvoxamine. Meanwhile, the genes encoding these isoenzymes have a high level of polymorphism, which may affect the protein synthesis
%K pharmacogenetics
%K SSRIs
%K fluvoxamine
%K biotransformation
%K personalized medicine
%K CYP2D6
%K depressive disorders
%K alcohol addiction
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029588/